NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer

By afschroeder • June 27, 2025

Braunstein LZ, Mitchell MP, Bandos H, Sikov WM, Khan AJ, Chen PY, Ganz PA, Jagsi R, White JR, Cecchini RS, Kang H, Puhalla SL, Bolton KL, Connolly EP, Stringer-Reasor EM, Gergelis KR, Julian TB, Mamounas EP, Wolmark N. NRG-BR008/HERO study: a Phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer. Future Oncol. 2025 Jun 26:1-9. doi: 10.1080/14796694.2025.2511586. Epub ahead of print. PMID: 40574381.

Tags: adjuvant breast radiotherapy, Breast cancer treatment, Breast-conservation therapy, Hematology/Oncology, HER2-positive breast cancer, HER2-targeted therapy, oncological outcomes, Publications, quality of life outcomes

Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy

Haidar AJ, Chen A, Chen JL, Al-Hashimi S, Ghaffari RS, Fung S, Silverstein J, Konecny GE, Tsui E. Ocular Toxic Effects During Mirvetuximab Soravtansine Therapy.[...]

Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion of Patients with Brain Metastases and Leptomeningeal Disease

Riano I, Velez MA, Pomares-Millan H, Blaquier J, Peshin S, Feldman J, Velazquez AI. Expanding Lung Cancer Clinical Trial Criteria: A Systematic Review on Inclusion[...]

Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast and ovarian cancer

Thaker SK, Silverstein J, Konecny GE, Bardia A. Trastuzumab deruxtecan and the evolving role of human epidermal growth factor receptor 2-targeted antibody-drug conjugates in breast[...]